Artigos Científicos
Lung Cancer Therapy: The Role of Personalized Medicine
04 março 2025
link
Copiado!
Lung cancer is the deadliest cancer globally, often diagnosed late due to nonspecific symptoms, leading to poor outcomes. Treatment choices, especially for non-small cell lung cancer (NSCLC), the most common type, require careful consideration of the tumor’s histology and genetic profile. NSCLC’s high mutational load makes next-generation sequencing (NGS) essential for identifying mutations and selecting targeted therapies. Personalized medicine, which tailors’ treatments based on individual genetic factors, is crucial in improving survival and quality of life. This article reviews the current therapeutic approaches for various lung cancer types and highlights advancements in emerging therapies that enhance treatment precision through personalization.
Lung Cancer Therapy: The Role of Personalized Medicine
by Raquel Ramos1,2,3
, Conceição Souto Moura 4, Mariana Costa3, Nuno Jorge Lamas 3,5,6, Renato Correia 7, Diogo Garcez 7, José Miguel Pereira 8, Thomas Lindahl 9, Carlos Sousa 1,3 and Nuno Vale 1,2,10,*
1
PerMed Research Group, RISE-Health, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal
2
RISE-Health, Department of Pathology, Faculty of Medicine, University of Porto, Alameda Professor Hernâni Monteiro, 4200-319 Porto, Portugal
3
Molecular Diagnostics Laboratory, Unilabs Portugal, Centro Empresarial Lionesa Porto, Rua Lionesa, 4465-671 Leça do Balio, Portugal
4
Pathology Laboratory, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal
5
Anatomic Pathology Service, Pathology Department, Centro Hospitalar Universitário de Santo António (CHUdSA), Largo Professor Abel Salazar, 4099-001 Porto, Portugal
6
Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, Rua da Universidade, 4710-057 Braga, Portugal
7
Technology & Innovation Department, Unilabs Portugal, Rua Manuel Pinto de Azevedo 173, 4100-321 Porto, Portugal
8
Radiology Department, Unilabs Portugal, Rua de Diogo Botelho 485, 4150-255 Porto, Portugal
9
Unilabs Group Services, Succursale d’Unilabs, Laboratoire d’Analyses Médicales SA, Rue de Lausanne 15, 1201 Geneva, Switzerland
10
Laboratory of Personalized Medicine, Department of Community Medicine, Health Information and Decision (MEDCIDS), Faculty of Medicine, University of Porto, Rua Doutor Plácido da Costa, 4200-450 Porto, Portugal
*
Author to whom correspondence should be addressed.
Cancers 2025, 17(5), 725; https://doi.org/10.3390/cancers17050725
Submission received: 19 December 2024 / Revised: 18 February 2025 / Accepted: 19 February 2025 / Published: 21 February 2025
(This article belongs to the Special Issue Pre-Clinical Studies of Personalized Medicine for Cancer Research)
